A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

2022-501363-40-00 Protocol NAV-1003 Human pharmacology (Phase I) - Other Ended

Start 17 Mar 2023 · End 22 Aug 2024 · Status Ended · 7 EU/EEA countries · 27 sites · Protocol NAV-1003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 110
Countries 7
Sites 27

Advanced or metastatic solid tumors with a KRAS-G12C mutation

Key facts

Sponsor
Navire Pharma Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
17 Mar 2023 → 22 Aug 2024
Decision date (initial)
2023-07-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-501363-40-00
ClinicalTrials.gov
NCT05480865

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced or metastatic solid tumors with a KRAS-G12C mutation

VersionLevelCodeTermSystem organ class
21.1 PT 10028980 Neoplasm 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Navire Pharma Inc.

Sponsor organisation
Navire Pharma Inc.
Address
1800 Owens Street Floor 12th
City
San Francisco
Postcode
94158-2388
Country
United States

Scientific contact point

Organisation
Navire Pharma Inc.
Contact name
David van Veenhuyzen

Public contact point

Organisation
Navire Pharma Inc.
Contact name
David van Veenhuyzen

Locations

7 EU/EEA countries · 27 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 7 2
Denmark Ended 3 1
France Ended 15 6
Greece Ended 15 5
Italy Ended 15 4
Netherlands Ended 10 2
Spain Ended 10 7
Rest of world
Australia
35

Investigational sites

Belgium

2 sites · Ended
Grand Hopital de Charleroi
Oncology, Grand Rue 3, 6000, Charleroi
CHU De Liege
Oncology, Avenue De L'hopital 1, 4000, Liege

Denmark

1 site · Ended
Rigshospitalet
Department of Oncology, Blegdamsvej 9, 2100, Copenhagen Oe

France

6 sites · Ended
Centre Hospitalier Universitaire Grenoble Alpes
Pneumology, Boulevard De La Chantourne, Cs 10217 La Tronche, Grenoble Cedex 9
Centre Hospitalier Universitaire De Rennes
Pneumology, 2 Rue Henri Le Guilloux, 35000, Rennes
Centre Oscar Lambret
Medical oncology, 3 Rue Frederic Combemale, 59000, Lille
Centr Georges Francois Leclerc
Medical oncology, 1 Rue Professeur Marion, 21000, Dijon
Institut Bergonie
Medical oncology, 229 Cours De L Argonne, 33000, Bordeaux
Assistance Publique Hopitaux De Paris
Oncology department, 46 Rue Henri Huchard, 75877, Paris Cedex 18

Greece

5 sites · Ended
St. Luke's Hospital S.A.
Department of Oncology, Harilaou Trikoupi Str. 3, 552 36, Thessaloniki
University General Hospital Of Heraklion
Department of Medical Oncology, Stavrakia And Voutes, 715 00, Heraklion
Athens Medical Center S.A. - The European Interbalkan Medical Center in Thessaloniki
Department of Medical Oncology, 10 Asklipiou Street, Thessaloniki
Thoracic General Hospital Of Athens I Sotiria
3rd Department of Internal Medicine of University of Athens, Oncology Unit, Messogion Avenue 152, 115 27, Athens
University General Hospital Attikon
2nd Propaeudeutic Internal Medicine Clinic, Oncology Unit, Rimini Street 1, 124 62, Athens

Italy

4 sites · Ended
Careggi University Hospital
SODc Medical Oncology, Largo Giovanni Alessandro Brambilla 3, 50134, Florence
Azienda Ospedaliera Universitaria - Universita' Degli Studi Della Campania Luigi Vanvitelli
UOC Onco-hematology, Piazza Luigi Miraglia 2, 80138, Naples
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Unit of Melanoma, Cancer lmmunotherapy and Development, Via Mariano Semmola 52, 80131, Naples
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
UOC medical oncology, Piazzale Spedali Civili 1, 25123, Brescia

Netherlands

2 sites · Ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Thoraxoncology, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Netherlands Cancer Institute
Lung Cancer and Thoracic Oncology, Plesmanlaan 121, 1066 CX, Amsterdam

Spain

7 sites · Ended
University Clinic Of Navarra
Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Virgen De La Macarena
Oncology, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D Hebron 119-129, 08035, Barcelona
Hospital Universitario Virgen De La Victoria
Oncology, Calle Del Arroyo Teatinos S N, 29010, Malaga

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2023-11-09 2024-01-18 2024-04-09
France 2023-03-17 2023-03-28 2024-04-09
Greece 2023-11-28
Italy 2023-08-11 2023-10-24 2024-04-09
Netherlands 2023-10-16 2023-11-21 2024-04-09
Spain 2023-05-04 2023-06-01 2024-04-09

Application history

14 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-09-02 Spain Acceptable
2023-01-09
2023-01-12
2 SUBSTANTIAL MODIFICATION SM-1 2023-02-06 Spain Acceptable 2023-03-01
3 SUBSTANTIAL MODIFICATION SM-2 2023-02-14 Acceptable 2023-04-12
4 SUBSTANTIAL MODIFICATION SM-3 2023-02-28 Acceptable 2023-04-26
5 SUBSTANTIAL MODIFICATION SM-4 2023-02-28 Acceptable 2023-05-04
6 SUBSEQUENT ADDITION OF MSC APP-6 2023-04-21 Acceptable
2023-01-09
2023-07-18
7 SUBSEQUENT ADDITION OF MSC APP-7 2023-04-21 Acceptable
2023-01-09
2023-07-10
8 SUBSEQUENT ADDITION OF MSC APP-8 2023-04-21 Acceptable
2023-01-09
2023-07-10
9 SUBSTANTIAL MODIFICATION SM-5 2023-06-13 Acceptable 2023-07-12
10 SUBSTANTIAL MODIFICATION SM-6 2023-08-25 Acceptable 2023-10-17
11 NON SUBSTANTIAL MODIFICATION NSM-1 2023-10-24 Spain Acceptable 2023-10-24
12 NON SUBSTANTIAL MODIFICATION NSM-2 2023-10-31 Acceptable
13 NON SUBSTANTIAL MODIFICATION NSM-3 2023-10-31 Spain 2023-10-31
14 SUBSTANTIAL MODIFICATION SM-8 2024-02-24 Spain Acceptable
2024-04-08
2024-04-08